Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Camphorated opium tincture
0309020N0AAABAB
|
Opium camph | Powdered opium | Respiratory System | No data available |
|
Campto 100mg/5ml concentrate for solution for infusion vials
0801050Q0BBAAAA
|
Campto | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Campto 300mg/15ml concentrate for inf vials
0801050Q0BBACAC
|
Campto | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Campto 40mg/2ml concentrate for solution for infusion vials
0801050Q0BBABAB
|
Campto | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Canakinumab 150mg powder for solution for injection vials
0802040ACAAAAAA
|
Canakinumab | Canakinumab | Malignant Disease and Immunosuppression | No data available |
|
Canakinumab 150mg/1ml inj pre-filled disposable devices
0802040ACAAACAC
|
Canakinumab | Canakinumab | Malignant Disease and Immunosuppression | No data available |
|
Canakinumab 150mg/1ml solution for injection vials
0802040ACAAABAB
|
Canakinumab | Canakinumab | Malignant Disease and Immunosuppression | No data available |
|
Cancidas 50mg pdr for concentrate for inf vials
0502040C0BBAAAA
|
Cancidas | Caspofungin | Infections | No data available |
|
Cancidas 70mg powder for solution for infusion vials
0502040C0BBABAB
|
Cancidas | Caspofungin | Infections | No data available |
|
Candesartan 16mg/5ml oral solution
0205052C0AAAKAK
|
Candesartan cilexetil | Candesartan cilexetil | Cardiovascular System | No data available |
|
Candiden 1% cream
1310020H0BHAAAB
|
Candiden (Topical) | Clotrimazole | Skin | No data available |
|
Candiden 500mg pessaries
0702020F0BDAAAF
|
Candiden (Vaginal) | Clotrimazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Candox 10mg modified-release tablets
0407020ADBGAAAF
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 20mg modified-release tablets
0407020ADBGABAG
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 40mg modified-release tablets
0407020ADBGADAH
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 5mg modified-release tablets
0407020ADBGACAK
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 80mg modified-release tablets
0407020ADBGAEAI
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
CanesMeno Multi Support tablets
091000000BBYMCB
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
CanesMeno Night tablets
091000000BBYNCC
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
CanesOasis Cystitis Relief 4g gran for soln sachets
0704030J0BPAAAI
|
CanesOasis | Sodium citrate | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Canesten AF Dual Action 1% powder
1310020H0BBAFAD
|
Canesten (Topical) | Clotrimazole | Skin | No data available |
|
Canesten AF Dual Action 1% spray
1310020H0BBAGAE
|
Canesten (Topical) | Clotrimazole | Skin | No data available |
|
Canesten Dermatological 1% powder
1310020H0BBADAD
|
Canesten (Topical) | Clotrimazole | Skin | No data available |
|
Canesten Oasis 4g oral granules sachets cranberry
0704030J0BJABAI
|
Canesten Oasis | Sodium citrate | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Canesten Oasis 4g oral granules sachets lemon
0704030J0BJAAAI
|
Canesten Oasis | Sodium citrate | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.